Dashboard
Manage Tickers

BIIB BIOGEN INC.

Nasdaq biogen.com


$ 166.44 $ 2.58 (1.57 %)    

Tuesday, 18-Nov-2025 10:39:06 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 593.58 $ -6.05 (-1.01 %)
DIA $ 460.48 $ -1.68 (-0.36 %)
SPY $ 657.83 $ -4.30 (-0.65 %)
TLT $ 89.32 $ -0.03 (-0.03 %)
GLD $ 373.56 $ -1.28 (-0.34 %)
$ 164.68
$ 163.59
$ 166.18 x 3
$ 166.68 x 4
$ 163.21 - $ 166.98
$ 110.04 - $ 169.00
2,245,006
na
24.16B
$ 0.48
$ 15.02
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-12-2025 12-31-2024 10-K
5 10-30-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 04-24-2024 03-31-2024 10-Q
8 02-14-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 07-25-2023 06-30-2023 10-Q
11 04-25-2023 03-31-2023 10-Q
12 02-15-2023 12-31-2022 10-K
13 10-25-2022 09-30-2022 10-Q
14 07-20-2022 06-30-2022 10-Q
15 05-03-2022 03-31-2022 10-Q
16 02-03-2022 12-31-2021 10-K
17 10-20-2021 09-30-2021 10-Q
18 07-22-2021 06-30-2021 10-Q
19 04-22-2021 03-31-2021 10-Q
20 02-03-2021 12-31-2020 10-K
21 10-21-2020 09-30-2020 10-Q
22 07-22-2020 06-30-2020 10-Q
23 04-23-2020 03-31-2020 10-Q
24 02-06-2020 12-31-2019 10-K
25 10-22-2019 09-30-2019 10-Q
26 07-24-2019 06-30-2019 10-Q
27 04-24-2019 03-31-2019 10-Q
28 02-06-2019 12-31-2018 10-K
29 10-23-2018 09-30-2018 10-Q
30 07-24-2018 06-30-2018 10-Q
31 04-24-2018 03-31-2018 10-Q
32 02-01-2018 12-31-2017 10-K
33 10-24-2017 09-30-2017 10-Q
34 07-25-2017 06-30-2017 10-Q
35 04-25-2017 03-31-2017 10-Q
36 02-02-2017 12-31-2016 10-K
37 10-26-2016 09-30-2016 10-Q
38 07-21-2016 06-30-2016 10-Q
39 04-21-2016 03-31-2016 10-Q
40 02-03-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Biogen And Stoke Therapeutics Highlight Ur...
11/17/2025 12:38:39

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden...

the-committee-for-medicinal-products-for-human-use-of-the-european-medicines-agency-adopted-a-positive-opinion-recommending-the-approval-of-biogens-high-dose-regimen-of-nusinersen-for-5q-spinal-muscular-atrophy-final-decision-expected-in-january-2026
The Committee For Medicinal Products For H...
11/17/2025 11:02:30

If adopted by the European Commission, the high dose regimen will be an additional dosing option to the already approved 12 mg ...

reported-earlier-eisai-and-biogen-announce-united-kingdom-approval-of-leqembi-lecanemab-iv-maintenance-dosing-for-early-alzheimers-disease
Reported Earlier, Eisai And Biogen Announc...
11/14/2025 08:11:43

stifel-upgrades-biogen-to-buy-raises-price-target-to-202
Stifel Upgrades Biogen to Buy, Raises Pric...
11/06/2025 12:45:56

Stifel analyst Paul Matteis upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and raises the price target from $144 to $202.

bernstein-maintains-market-perform-on-biogen-raises-price-target-to-157
Bernstein Maintains Market Perform on Biog...
11/03/2025 12:49:03

Bernstein analyst William Pickering maintains Biogen (NASDAQ:BIIB) with a Market Perform and raises the price target from $1...

biogen-to-highlight-translational-rnaseq-findings-and-preservation-of-humoral-immunity-in-felzartamab-treated-iga-nephropathy-patients
Biogen To Highlight Translational RNAseq F...
11/03/2025 12:38:19

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights int...

rbc-capital-maintains-outperform-on-biogen-lowers-price-target-to-210
RBC Capital Maintains Outperform on Biogen...
10/31/2025 14:33:39

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $217 to...

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

biogen-lowers-fy2025-adj-eps-guidance-from-1550-1600-to-1450-1500-vs-1580-est-sees-sales-9676b-9773b-vs-9686b-est
Biogen Lowers FY2025 Adj EPS Guidance from...
10/30/2025 11:06:18

Biogen (NASDAQ:BIIB) lowers FY2025 Adj EPS guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 analyst estimate. sees sales ...

biogen-lowers-fy2025-adj-eps-guidance-from-1550-1600-to-1450-1500-vs-1580-est
Biogen Lowers FY2025 Adj EPS Guidance from...
10/30/2025 10:53:34

Biogen (NASDAQ:BIIB) lowers FY2025 Adj EPS guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 analyst estimate. Increased e...

biogen-q3-adj-eps-481-beats-388-estimate-sales-2534b-beat-2339b-estimate
Biogen Q3 Adj. EPS $4.81 Beats $3.88 Estim...
10/30/2025 10:52:27

Biogen (NASDAQ:BIIB) reported quarterly earnings of $4.81 per share which beat the analyst consensus estimate of $3.88 by 23.91...

examining-the-future-biogens-earnings-outlook
Examining the Future: Biogen's Earnings Ou...
10/29/2025 17:02:03

Core News & Articles
Reported Sunday, Eisai and Biogen Receive ...
10/27/2025 06:22:40

biogens-immunology-pipeline-has-long-term-potential-analyst
Biogen's Immunology Pipeline Has Long-Term...
10/24/2025 16:47:04

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across mul...

biogen-and-vanqua-bio-announce-agreement-granting-biogen-exclusive-worldwide-rights-to-vanquas-c5ar1-antagonist-vanqua-to-receive-70m-upfront-and-up-to-990m-in-miletones
Biogen And Vanqua Bio Announce Agreement G...
10/24/2025 11:32:46

biogen-to-present-data-from-trials-evaluating-dapirolizumab-pegol-at-american-college-of-rheumatology-convergence-2025-in-chicago
Biogen To Present Data From Trials Evaluat...
10/22/2025 11:37:56

Biogen Inc. (Nasdaq: BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc...

small-cap-biotech-climb-bios-lead-drug-candidate-has-larger-long-term-opportunity
Small-Cap Biotech Climb Bio's Lead Drug Ca...
10/16/2025 17:40:28

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...

biogen-says-estimated-charge-expected-to-impact-gaap--non-gaap-net-income-per-diluted-share-for-q3-by-001-per-share-expects-q3-results-to-include-acquired-in-process-rd-upfront-and-milestone-expense-of-about-2m-on-pre-tax-basis
Biogen Says Estimated Charge Expected To I...
10/14/2025 20:23:09

- SEC Filing

7-analysts-have-this-to-say-about-biogen
7 Analysts Have This To Say About Biogen
10/10/2025 19:00:46

morgan-stanley-maintains-equal-weight-on-biogen-raises-price-target-to-149
Morgan Stanley Maintains Equal-Weight on B...
10/10/2025 17:36:30

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION